September, 2024
Asundexian versus Apixaban in Patients with Atrial Fibrillation.

August, 2024
Rivaroxaban for Patients with Intermittent Claudication.

August, 2024
Predictors of Bleeding and Thrombotic Events in Hospitalized Patients with COVID-19 and Elevated D-dimer: Insights from the ACTION Randomized Clinical Trial.

July, 2024
Effect of Apixaban on Clinical Outcomes in Outpatients with COVID-19: The APOLLO Randomized Clinical Trial.

June, 2024
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19.

June, 2024
Venous Thromboembolism Risk Models in Hospitalized Patients: Time for Implementation, Not Endless Development.

April, 2024
Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Much as Protamine Sulfate.

April, 2024
Biomarker profile in provoked versus unprovoked deep vein thrombosis.

April, 2024
Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial infarction.

February, 2024
Prevention and treatment of venous thromboembolism. International Consensus Statement. Guidelines based on scientific evidence.

December, 2023
Effects of long-pulsed 1064 nm Nd:YAG laser on telangiectasias and reticular veins: an in vivo histological study in humans.

August, 2023
Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalization for COVID-19: an economic modeling study.

July, 2023
A novel therapeutic vaccine targeting the soluble TNFα II receptor to limit the progression of cardiovascular disease: AtheroVax™.

April, 2023
Efficacy and safety of ixekizumab versus low-dose IL-2 versus colchicine versus standard of care in the treatment of hospitalized patients with moderate to critical COVID-19: a pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).

April, 2023
Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.

January, 2023
Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: an open-label study.

October, 2022
International Society on Thrombosis and Haemostasis guidelines for antithrombotic treatment in COVID-19.

October, 2022
Impact of dermoscopy on pre-treatment evaluation of telangiectasias of the lower limbs: a prospective study.

April, 2022
Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial.

January, 2022
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalization for COVID-19 (MICHELLE): an open-label, multicenter, randomized, controlled trial.

January, 2022
Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecologic cancer surgery: the VALERIA study.

January, 2022
Prospective study evaluating response patterns to the Caprini score to prevent venous thromboembolism after interventional treatment for varicose veins.

January, 2022
Rivaroxaban plus aspirin versus aspirin for peripheral arterial disease and intermittent claudication – Rationale and Design of the COMPASS CLAUDICATION Study.

September, 2021
Hospitalized, clinically ill patients for extended COVID-19 thrombosis prophylaxis with rivaroxaban. Therapy: rationale and design of The MICHELLE TRIAL.

July, 2021
An update on the pathogenesis of COVID-19 and the reportedly rare thrombotic events following vaccination

June, 2021
Therapeutic versus prophylactic anticoagulation for hospitalized patients with COVID-19 and elevated D-dimer concentration: an open-label, multicenter, randomized, controlled trial

April, 2021
Randomized clinical trial to evaluate a routine complete anticoagulation strategy in patients with coronavirus (SARS-CoV2) infection admitted to hospital: Rationale and design of ACTION (AntiCoagulaTlon cOroNavirus) – Phase 4

December, 2020
Comparative studies on the anticoagulant profile of branded enoxaparin and a new biosimilar version

December, 2020
Drug interactions of 257 antineoplastic agents and supportive care with 7 anticoagulants: a comprehensive review of interactions and mechanisms

December, 2020
Evidence-Based Practical Guidance for Antithrombotic Management in Patients with Coronavirus Disease (COVID-19) in 2020

December, 2020
Assay-based differentiation in the neutralization profile of unfractionated heparin, enoxaparin and fondaparinux by Andexanet Alfa

June, 2020
Rationale and design for the study Apixaban versus Clopidogrel on a background of aspirin in a patient undergoing infraplastic angioplasty for critical limb ischemia: the AGRIPPA trial

June, 2020
Guidelines on the diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper from the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cell Therapy

December, 2019
Oral anticoagulants and management of cancer-associated thrombosis. Where will we be in 2019?

December, 2019
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for vascular dose and dual pathway inhibition

December, 2019
Heparin shortage crisis in porcine mucosa! What are the options?

December, 2019
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

December, 2019
Zika and Chikungunya viruses and risk of venous thromboembolism

October, 2019
Is it time for a specific score to assess venous thromboembolism risk for non-solid tumors?

May, 2019
Effect of a multifaceted quality improvement intervention on evidence-based treatment prescription in patients at high cardiovascular risk in Brazil: the BRIDGE Cardiovascular Prevention Cluster randomized clinical trial

May, 2019
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation

February, 2019
Rivaroxaban for thromboprophylaxis in high-risk outpatients with cancer

December, 2018
Rivaroxaban for post-discharge thromboprophylaxis: the MARINER study

December, 2018
Edoxaban para tratamento de tromboembolismo venoso – a novidade para a América Latina. Um guia prático

November, 2018
Efficacy and safety of a biosimilar versus brand-name enoxaparin in the prevention of venous thromboembolism after major abdominal surgery: a prospective, single-blind, multicenter, randomized clinical trial

August, 2018
Medical management of stable peripheral arterial disease: the COMPASS study. Perspectives from a vascular perspective

February, 2018
Early vein recanalization in patients with DVT treated with rivaroxaban